Please login to the form below
Daichii Sankyo
This page shows the latest Daichii Sankyo news and features for those working in and with pharma, biotech and healthcare.
Astellas, Daiichi Sankyo and Takeda to study biomarkers
Collaboration aims to establish comprehensive database to accelerate drug development. . Japanese pharmaceutical firms Astellas, Daiichi Sankyo and Takeda have joined forces to create a comprehensive database of biomarkers from healthy adults.
Latest news
-
AZ and Daiichi Sankyo sign Movantik marketing deal
AstraZeneca has announced a new co-commercialisation agreement with Daiichi Sankyo for the constipation drug Movantik (naloxegol) in the US. . ... AstraZeneca will be responsible for all manufacturing, will book all sales and will make sales-related
-
Thin on the ground
Daichii Sankyo is developing edoxaban tosylate, which is also an orally active direct factor Xa inhibitor.
-
News in brief, June 20, 2007
Its clients include US and EU pharmaceutical and biotechnology corporations including Allergan, Biogen Idec, Bristol-Myers Squibb, sanofi-aventis and Daichii Sankyo.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and benefits
-
Project Manager/ Account Manager
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
-
Account Director, Medical Education
-
Salary TBC
-
Digital Account Director
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
Subscribe to our email news alerts
- Drug launches to watch in 2019
- Welcome to the Communique Awards - Communiqué Awards 2018
- ‘Inflexible’ NICE blocking access to rare disease drugs
- 2019: CRISPR and therapeutic gene editing comes of age
- GW Pharma's cannabis-based medicine to be tested in dementia
- More good news, and some bad, for Merck’s Keytruda
- BioMarin prepares for haemophilia A gene therapy data readout, filing
- Innovent gears up for PD-1 inhibitor launch in China
- NICE knocks back BioMarin’s Batten disease drug
- Amgen, Servier start second phase 3 trial of heart failure hope
- The importance of co-creation with patients
- McCann Health's next challenge: creative differentiation
PMHub
Nobull Communications
Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...
Latest intelligence
- The importance of co-creation with patients
- Overcoming the barriers...
- Three billboards on the road to multichannel
- Chris Ross examines the trends driving multichannel communication in 2019...
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
